Saturday 17 October 2026
Export GTBP’s income statement to Excel — free account
GT Biopharma, Inc.
GTBP Healthcare Biotechnology
In the quarter to June 2026, EPS grew 98.9% and free cash flow fell 41.3%, each against the same quarter a year earlier.
7.03
0.33
−4.48%
Follow GTBP
GT Biopharma, Inc. (GTBP) P/E ratio
GT Biopharma, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.5× (August 2015) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2015 | 0.0× | — |
| Jun 2015 | 0.4× | — |
| Mar 2015 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.5×
Ten-year median
0.0×
Current reading's percentile
91
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DARE Dare Bioscience, Inc. compare | n/m |
| GTBP GT Biopharma, Inc. | n/m |
| TVRD Tvardi Therapeutics, Inc. compare | n/m |
| CNSY Cerenome, Inc. compare | n/m |
| MRKR MARKER THERAPEUTICS, INC. compare | n/m |
| AKTX Akari Therapeutics PLC compare | n/m |
| NCEL NewcelX Ltd. compare | n/m |
| ADAPY Adaptimmune Therapeutics PLC compare | n/m |
| VAXX Vaxxinity, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)